<DOC>
	<DOCNO>NCT00673179</DOCNO>
	<brief_summary>The goal clinical research study learn give certain combination chemotherapy drug surgery , mostly outpatient clinic instead hospital , result few hospital stay treatment osteosarcoma . The drug schedule vary depend status cancer level risk spreading , include combination doxorubicin ( non-liposomal ) , cisplatin , methotrexate , ifosfamide , describe .</brief_summary>
	<brief_title>Doxorubicin With Cisplatin , High-Dose Methotrexate , Additional Risk-Adapted Outpatient Chemotherapy</brief_title>
	<detailed_description>The Study Drugs : The standard treatment combination use treat patient osteosarcoma doxorubicin , cisplatin , methotrexate without ifosfamide . When treatment combination give hospital , require around 18-22 hospital stay . Somewhat recently , chemotherapy osteosarcoma become possible give outpatient clinic . Researchers want learn give 4 certain drug ( combination doxorubicin , cisplatin , methotrexate without ifosfamide ) outpatient set eligible patient help decrease number hospital stay . During study , study participant whose tumor ( ) take surgery offer routine surgery remove tumor ( ) . After surgery , doctor believe tumor ( ) respond well enough , standard treatment combination doxorubicin , cisplatin , methotrexate . If tumor ( ) respond well enough , however , standard treatment combination methotrexate ifosfamide . In study , participant consider `` high risk '' tumor ( ) spread lung follow case : participant 's tumor ( ) large time join study , cancer spread organ , and/or standard chemotherapy study kill enough tumor cell . The following drug use study : - Doxorubicin design stop growth cancer cell , may cause cell die . - Cisplatin atom center contain type metal call platinum . The platinum suppose poison cancer cell . - Methotrexate design disrupt cell ( include cancer cell ) make repair DNA `` copying '' . - Ifosfamide design stop growth cancer cell , may cause cell die . Study Groups : If find eligible take part study , assign 1 2 group base likelihood surgery able control disease arm leg bone tumor ( ) . Group 1 include participant consider `` standard '' chance surgery able control disease arm leg , participant amputation , participant cancer area arm leg time diagnosis . Group 2 include participant consider `` high '' chance tumor ( ) leave behind surgery doctor considers `` incomplete '' control disease . Central Venous Line : For drug give vein , study doctor likely recommend central venous line ( CVL ) place . A central venous line sterile flexible tube place large vein local anesthesia . Your doctor explain procedure detail , require sign separate consent form procedure . Pre-Surgery Chemotherapy Group 1 : Before surgery , Group 1 participant receive doxorubicin , cisplatin , methotrexate follow leucovorin . Leucovorin give help prevent and/or treat side effect methotrexate may cause . Dexrazoxane use decrease risk side effect heart doxorubicin may cause . These drug give outpatient clinic ( without require hospitalization ) , possible . Doxorubicin give vein 15 minute , dexrazoxane vein 15 minute , Day 1 Weeks 1 6 . Cisplatin give continuous infusion vein 48 hour , Days 1 2 Weeks 1 6 . Methotrexate give vein , 4 hour , Day 1 Weeks 4 , 5 , 9 , 10 . If difficulty recover effect methotrexate therapy , may receive methotrexate twice surgery , instead 4 time . Leucovorin give vein , 5 minute , day methotrexate dose mouth every 6 hour , study doctor believe methotrexate level blood low . The methotrexate level blood check use blood test ( le 2 teaspoon time ) . This test perform day methotrexate infusion , methotrexate blood level low consider safe stop leucovorin . Pre-Surgery Chemotherapy Group 2 : Before surgery , Group 2 participant receive dexrazoxane , doxorubicin , cisplatin . On Day 1 Weeks 1 , 4 , 7 , dexrazoxane give vein 15 minute , follow doxorubicin give vein 15 minute cisplatin artery 4 hour . Infusion artery require hospital stay 2-4 day . Surgery : For eligible study participant , surgery remove tumor ( ) perform either Week 11 12 . The surgery explain detail , ask sign separate consent form describe risk . Before surgery , routine visit surgeon . You several routine scan perform help plan surgery . Chemotherapy Regimens Surgery : After surgery ( around Week 14 ) , receive additional `` post-surgery '' chemotherapy . After surgery , originally Group 1 , doctor believe tumor ( ) respond well enough ( specifically , 90 % tumor cell dead check microscope ) , receive additional chemotherapy similar receive surgery . This described Regimen A . If doctor believe tumor ( ) respond well enough ( less 90 % tumor cell dead check microscope ) , however , assign Regimen B . All participant start Group 2 assign Regimen B . Radiation Chemotherapy Patients Ineligible Routine Surgery : A small number participant study may need radiation therapy help control disease , part routine care . This would do tumor ( ) completely take surgery , amputation necessary refuse participant . If need , depend tumor ( ) locate , doctor may decide radiation need . All participant need radiation surgery doctor considers `` incomplete '' control disease consider `` high risk '' receive Regimen B therapy radiation . ( Radiation usually begin Weeks 12-14 , could anytime ifosfamide therapy . ) The radiation therapy explain detail , ask sign separate consent form describe risk . Post-Surgery Chemotherapy Regimen A : Regimen A include following treatment : - Methotrexate give 4 hour Day 1 Weeks 14 , 15 , 19 , 20 , 24 , 25 , 29 , 30 . - Doxorubicin give Day 1 Weeks 16 , 21 , 26 . - Cisplatin give continuous infusion vein 48 hour , Days 1 2 Weeks 16 , 21 , 26 . - Leucovorin give vein , 5 minute , day methotrexate dose mouth every 6 hour , study doctor believe methotrexate level blood low . The methotrexate level blood check use blood test ( le 2 teaspoon time ) . This test perform day methotrexate infusion , methotrexate blood level low consider safe stop leucovorin . Post-Surgery Chemotherapy Regimen B : Regimen B include follow treatment : - Methotrexate give 4 hour Day 1 Weeks 14 , 15 , 20 , 21 , 26 , 27 , 32 , 33 , 38 , 39 . - Leucovorin give vein , 5 minute , day methotrexate dose mouth every 6 hour , study doctor believe methotrexate level blood low . The methotrexate level blood check use blood test ( le 2 teaspoon time ) . This test perform day methotrexate infusion , methotrexate blood level low consider safe stop leucovorin . - Ifosfamide give vein , continuously 5 day time , Weeks 16 , 22 , 28 , 34 . - Mesna give vein , continuously 6 day time , Weeks 16 , 22 , 28 , 34 . Mesna use decrease risk bleed bladder kidney ifosfamide take . Study Tests : After Week 5 treatment , surgery , follow test perform : - Your medical history review . - You physical exam . - Blood ( 2-3 teaspoon time ) collect routine test test kidney liver function . The routine blood test may repeat often week receive study drug . If receive cisplatin , may hear test perform dose drug . You ECHO perform fourth dose doxorubicin Week 14 , possibly often necessary . Questionnaires : You ask complete 5 brief questionnaire 5 different day study . The questionnaire ask health-related quality life , include question felt , physically emotionally , cancer treatment . The questionnaire also ask family adapt cancer treatment , effect medicine may whether felt healthy sick . These questionnaire complete Week 1 , Week 7 ( surgery radiation ) , sometime Weeks 20-22 , end-of-treatment visit ( either end-of-Regimen-A visit , end-of-Regimen-B visit , end-of-treatment visit ) , 1 year first diagnosis cancer . It take 15-20 minute fill questionnaires time . External Care : If study doctor allow agree , blood test study may perform outside M. D. Anderson . The study doctor discus option , applicable . Length Study Participation : If disease get bad intolerable side effect occur , take study . End-of-Regimen-A Visit , End-of-Regimen-B Visit , End-of-Treatment Visit : If complete Regimen A B plan leave study early reason , follow procedure perform : - You physical exam . - Urine blood ( 2-3 teaspoon ) draw routine test test kidney liver function . - You ECHO , x-rays disease area chest , CT scan chest , bone scan . - You also whole-body scan hear test . Follow-Up Visits : After end-of-Regimen-A visit , end-of-Regimen-B visit , end-of-treatment visit , ask return follow-up visit . At visit , follow procedure perform : - CT scan chest perform every 3 month first year chemotherapy end , every 4 month 2nd year , every 6 month 3rd year , year next 2 year . - You bone scan every year 5 year . This investigational study . All drug use study commercially available commonly use osteosarcoma . This study design look drug ' use outpatient setting , consider research . Up 40 patient take part study . All enrol M. D. Anderson .</detailed_description>
	<mesh_term>Osteosarcoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Dexrazoxane</mesh_term>
	<mesh_term>Razoxane</mesh_term>
	<criteria>1 . Newly diagnose highgrade osteosarcoma . Patients unresectable metastatic disease ARE eligible . 2 . Age 540 year old date diagnostic biopsy . 3 . Adequate organ function : creatinine 1.6 low , bilirubin &lt; 2 , Hemoglobin 8 gm/dL great , Absolute neutrophil count ( ANC ) 1000 , platelets 100,000 . Cardiac ejection fraction ( EF ) 50 % good , hear threshold 40 dB 4000 Hz well . 4 . Signed informed consent . 5 . Negative pregnancy test females child bear potential , sexually active , willingness use effective contraception chemotherapy . 1 . Diagnosis osteosarcoma . 2 . Pregnant lactating female , unwilling use effective contraception chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Doxorubicin</keyword>
	<keyword>AD</keyword>
	<keyword>Hydroxydaunomycin hydrochloride</keyword>
	<keyword>Cisplatin</keyword>
	<keyword>Paraplatin®</keyword>
	<keyword>Methotrexate</keyword>
	<keyword>Ifosfamide</keyword>
	<keyword>Osteosarcoma</keyword>
	<keyword>Sargramostim</keyword>
	<keyword>Leukine™</keyword>
	<keyword>Leucovorin</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Gemzar</keyword>
	<keyword>Gemcitabine Hydrochloride</keyword>
	<keyword>GM-CSF</keyword>
	<keyword>Questionnaire</keyword>
	<keyword>Survey</keyword>
</DOC>